Getting your Trinity Audio player ready...

The influencer ‘Roaring Kitty’ shook the stock markets with the ‘meme stock’ phenomenon, with GameStop, Inc. (NYSE: GME) becoming his most notable trade. Meme stocks have generated substantial wealth for traders, and it seems Roaring Kitty is now broadening his scope. This feature offers insight into the stock’s worth monitoring in light of Roaring Kitty’s latest moves.

Chewy Inc. (NASDAQ: CHWY): Chewy experienced significant volatility on July 1 after a regulatory filing revealed that Roaring Kitty acquired a 6.6% stake. Roaring Kitty bought 9 million shares of the pet retailer, totaling over $261 million at a closing price of $29.05 per share on June 28. This made him the third-largest shareholder, with the stock gaining over 20% before markets opened on July 1.

Dyadic International Inc. (NASDAQ: DYAI): Dyadic International, a leader in cell culture solutions, announced a strategic partnership with Proliant Health and Biologicals (PHB) last month. PHB will provide $1.5 million upfront for developing high-volume, cost-effective cell culture products set to enter the $6 billion serum albumin market in the first half of 2025. Zacks SmallCap valued Dyadic at $9 a share in a July 1 report. Read entire report now.

Petco Health and Wellness Company Inc. (NASDAQ: WOOF): Petco released its 2023 ESG report last month, highlighting its commitment to pet owners, pets, and employees. The Petco Love initiative found homes for 142,924 pets in the 2023 fiscal year and donated $33.5 million to 2,000 animal welfare organizations and shelters. Petco also expanded its in-store veterinary hospitals to over 280 locations.

Intelligent Bio Solutions Inc. (NASDAQ: INBS): Intelligent Bio Solutions is gaining attention with its expansion into the UK market. The company announced that its Intelligent Fingerprinting Drug Screening System would be adopted by three major British retailers, with a combined employee strength of 55,000. Additionally, two major UK warehouse and logistics customers, with over 70 locations and 15,000 employees combined, will implement the screening system. The company also commenced dosing for its FDA-supporting pharmacokinetic study, with results expected by the end of July, and successfully completed the in-clinic portion of its PK study for the 510(k) pathway for regulatory approval.

Catheter Precision Inc. (NYSEAMERICAN: VTAK): Catheter Precision saw its stock surge 43.58% on July 1, hitting an intraday high of $0.84 per share after announcing unaudited revenues for the fiscal quarter and six months ended June 30, 2024. The company reported sales of its innovative LockeT and VIVO products. The VIVO system, a non-invasive 3D imaging technology, enhances the efficiency of ventricular ablation, aligning with the company’s expansion strategy. Read Entire Update Now!